Developing Therapeutics That Teach the Body to Heal Itself
Our team personally cares about the people we serve. We make progress every day to end suffering and premature death from serious human diseases. The Newsletter is one quick way keep track of AGT's advancements on all its programs and other events happening at the company. We look forward to keeping you up to date on our mission!
Newsletter Vol. 11 HIV Program Update Enrolled First Cohort Since our last Newsletter, AGT has enrolled its first cohort of six participants in its Phase 1 study of AGT103-T against HIV. Updates on the RePAIR Cl...
VOLUME 10 September 2020 Newsletter We’ve achieved a number of significant milestones this quarter, including the Food and Drug Administration (FDA) clearance to begin Phase 1 of our HIV cure program. The excit...
VOLUME 9 May 2020 Newsletter FDA Progress The Path to the Clinic For the HIV Cure This month, AGT saw tremendous progress with the FDA. FDA time and attention to our project has seemed to increase while agency...
A STELLAR 2019 Has Positioned AGT For A SPECTACULAR 2020. I wanted to take a moment to sum up a great year of progress and success at AGT and to talk about potential milestones and significant inflection points ...
Featured Stories AGT’s HIV cure program is nearing a major milestone: Investigational New Drug (IND) submission. The IND is the key document that reports the safety data the FDA requires prior to a human trial...
Newsletter Vol. 7 In wrapping up the year, AGT was proud to be featured as a State of Maryland “Success Story” for its growth in Maryland and achievements in the gene and cell therapy industry. Watch The Vid...
Subscribe to our newsletter to keep up to date with all the latest news about AGT!
